NTRX-07 Drug Asset Due Diligence Report 2026

This NTRX-07 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether NTRX-07 can convert its Small molecule drug profile and CB2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	NTRX-07 (query alias: NTRX-07)
Modality / target	Small molecule drug; CB2; CB2 agonists
Highest global status	Phase 2
Originator	Not disclosed
Active developers	NeuroTherapia, Inc.

The MCP disease footprint includes Alzheimer Disease, Neuroinflammation. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07058688	Phase 2	Recruiting	48	Primary endpoint not disclosed in English source
NCT06194552	Phase 1	Completed	32	Primary endpoint not disclosed in English source
NCT04375436	Phase 1	Completed	48	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

10 Year Follow-Up of 146 Advanced Stage NSCLC Patients Who Received Adenoviral Based Therapy

Not Applicable; n=146; evaluation: Positive. Reported fields: Mean survival = 334 Day (95%CI, 269 - 400); Mean survival = 334 Day (95%CI, 269 - 400)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

NTRX-07 addresses Alzheimer Disease, Neuroinflammation. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 15 matched transaction record(s) under the scope “target-level comparable: CB2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CB2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-04	MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1	Preclinical	Financial terms not disclosed
2025-10-15	SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio	Phase 2	Financial terms not disclosed
2025-03-24	MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Neuroprotective CB2 receptor agonists”. The milestone feed surfaced a patent-application signal described as “Oral cannabinoid receptor modulator formulations”. The milestone feed surfaced a patent-application signal described as “Heterocyclic modulators of cannabinoid receptors”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO